Treatment Limitations No disease-modifying therapies currently exist for CSVD
FDA has declined for now to approve the NDA for Anaphylm (dibutepinephrine), delaying the commercial entry of what could be the first oral alternative to Epipen
This peptide is known for its selective action, which means it can provide the benefits of increased growth hormone levels without many of the side effects associated with other growth hormone-releasing peptides
doi: 10.1007/BF02185763 57
Genetic analysis of AIP in 50 non-familial acromegalic patients resistant to treatment with SS analogs revealed a low, but non-negligible, prevalence of AIP germline mutations (62), suggesting a role for AIP alterations in SS-resistance of sporadic GH-secreting adenomas
Apply lip care products more frequently throughout the day, and consider a thicker formula at night for overnight conditioning